AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16151035 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill aerobic training (T‐AEX)
Number of subjects: 61
Study 16151035 — intervention group
Group type: COMPARATOR
Intervention: Reference rehabilitation program of stretching plus low‐intensity walking (R‐CONTROL)
Number of subjects: 61
Study 12570938 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasudil (4.5 mg intracoronarily)
Number of subjects: 18
Study 12570938 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group, n = 5)
Number of subjects: 18
Study 10212743 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine (PYR) 45 mg
Number of subjects: 12
Study 10212743 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8901300 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysteroscopic metroplasty
Number of subjects: 5
Study 1991701 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) at a dose of 250 mg/m2/day for 12 weeks
Number of subjects: 18
Study 1991701 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional radiation therapy
Number of subjects: 18
Study 6127861 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol 2% solution
Number of subjects: 10
Study 6127861 — intervention group
Group type: COMPARATOR
Intervention: Timolol 0.25% solution
Number of subjects: 10
Study 30676480 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan-based treatment
Number of subjects: 8342
Study 30257069 — intervention group
Group type: EXPERIMENTAL
Intervention: Luces de Cambio intervention (12-month family-based culturally tailored behavioral intervention)
Number of subjects: 297
Study 30257069 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 297
Study 26526421 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete revascularization
Number of subjects: 138
Study 26526421 — intervention group
Group type: COMPARATOR
Intervention: Incomplete revascularization
Number of subjects: 138
Study 26526421 — intervention group
Group type: COMPARATOR
Intervention: Post-operative complications, 30-day mortality, or 3-year survival
Number of subjects: 138
Study 24841107 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticyclic modulated ventilation (ACMV)
Number of subjects: 39
Study 24841107 — intervention group
Group type: COMPARATOR
Intervention: Continuous positive airway pressure (CPAP)
Number of subjects: 39
Study 23112415 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol
Number of subjects: 24
Study 19528154 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 day amoxicillin treatment
Number of subjects: 0
Study 19528154 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 day amoxicillin treatment
Number of subjects: 0
Study 17325591 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilvadipine
Number of subjects: 12
Study 17325591 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 12
Study 15140737 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual T2-weighted fast spin-echo
Number of subjects: 31
Study 15140737 — intervention group
Group type: EXPERIMENTAL
Intervention: T2-weighted fat-suppressed fast spin-echo
Number of subjects: 31
Study 15140737 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced T1-weighted fat-suppressed spin-echo
Number of subjects: 31
Study 15140737 — intervention group
Group type: EXPERIMENTAL
Intervention: Unenhanced and contrast-enhanced 3D time-of-flight MR angiography
Number of subjects: 31
Study 11571980 — intervention group
Group type: EXPERIMENTAL
Intervention: early postoperative intraperitoneal mitomycin C and 5-fluorouracil
Number of subjects: 248
Study 11571980 — intervention group
Group type: COMPARATOR
Intervention: surgery only
Number of subjects: 248
Study 10193369 — intervention group
Group type: EXPERIMENTAL
Intervention: Pranlukast (225 mg orally twice per day for four weeks)
Number of subjects: 17
Study 10193369 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 7822908 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve reconnection technique
Number of subjects: 30
Study 7822908 — intervention group
Group type: COMPARATOR
Intervention: Original Littler technique
Number of subjects: 30
Study 3342287 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 0
Study 3342287 — intervention group
Group type: EXPERIMENTAL
Intervention: Deuterium-labelled lidocaine
Number of subjects: 0
Study 3342287 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 0
Study 3342287 — intervention group
Group type: EXPERIMENTAL
Intervention: Deuterium-labelled bupivacaine
Number of subjects: 0
Study 30335712 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based progressive cervical strengthening program
Number of subjects: 83
Study 30335712 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 83
Study 30571173 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose methotrexate (15 mg/wk)
Number of subjects: 148
Study 30571173 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study 27475837 — intervention group
Group type: EXPERIMENTAL
Intervention: Icon condition (acetaminophen medications marked with an icon)
Number of subjects: 517
Study 27475837 — intervention group
Group type: COMPARATOR
Intervention: Non-icon condition (current labeling)
Number of subjects: 517
Study 24273022 — intervention group
Group type: EXPERIMENTAL
Intervention: Epratuzumab 360 mg/m2
Number of subjects: 90
Study 24273022 — intervention group
Group type: EXPERIMENTAL
Intervention: Epratuzumab 720 mg/m2
Number of subjects: 90
Study 24273022 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 23085132 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct mailing of DXA results and educational brochure
Number of subjects: 7500
Study 23085132 — intervention group
Group type: COMPARATOR
Intervention: Usual care (standard practice)
Number of subjects: 7500
Study 22027612 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptol 500 mg, 2 times daily in addition to regular vasoactive treatment
Number of subjects: 68
Study 22027612 — intervention group
Group type: COMPARATOR
Intervention: Regular treatment (control group)
Number of subjects: 68
Study 19006592 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine mouthwash (2 mg daily for 5 days)
Number of subjects: 82
Study 19006592 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (control)
Number of subjects: 82
Study 16796402 — intervention group
Group type: EXPERIMENTAL
Intervention: On-site rapid HIV testing at occupational clinics
Number of subjects: 7482
Study 16796402 — intervention group
Group type: COMPARATOR
Intervention: Off-site VCT using vouchers for rapid tests at free-standing centres
Number of subjects: 7482
Study 14570343 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin plus metronidazole (1 g cefazolin + 500 mg metronidazole)
Number of subjects: 160
Study 14570343 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin (2 g)
Number of subjects: 160
Study 10817729 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg of abacavir
Number of subjects: 25
Study 10817729 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.7 g of ethanol per kg of body weight
Number of subjects: 25
Study 10817729 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg of abacavir and 0.7 g of ethanol per kg
Number of subjects: 25
Study 8872401 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-age energy dosing (7 J, 30% higher than titration estimates)
Number of subjects: 35
Study 8872401 — intervention group
Group type: COMPARATOR
Intervention: Threshold titration
Number of subjects: 35
Study 8872401 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-age energy dosing
Number of subjects: 35
Study 8872401 — intervention group
Group type: COMPARATOR
Intervention: Threshold estimation strategy
Number of subjects: 35
Study 1325574 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative chemotherapy (4 weeks or 8 weeks arm of treatment with ACT D and VCR)
Number of subjects: 188
Study 1325574 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative chemotherapy
Number of subjects: 188
Study 6380982 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacid
Number of subjects: 21
Study 6380982 — intervention group
Group type: COMPARATOR
Intervention: Secretin
Number of subjects: 21
Study 30229405 — intervention group
Group type: EXPERIMENTAL
Intervention: Single coil shock vector
Number of subjects: 216
Study 30229405 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual coil shock vector
Number of subjects: 216
Study 30229405 — intervention group
Group type: COMPARATOR
Intervention: All successive internal shocks
Number of subjects: 216
Study 30229405 — intervention group
Group type: COMPARATOR
Intervention: Predictors of first shock failure
Number of subjects: 216
Study 30184600 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoreductive nephrectomy (CN) followed by interferon therapy
Number of subjects: 0
Study 30184600 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 0
Study 30184600 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoreductive nephrectomy (CN) followed by sunitinib
Number of subjects: 0
Study 30184600 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative nephrectomy (PN)
Number of subjects: 0
Study 30184600 — intervention group
Group type: COMPARATOR
Intervention: Angioembolisation
Number of subjects: 0
Study 27624781 — intervention group
Group type: EXPERIMENTAL
Intervention: PBMT
Number of subjects: 50
Study 27624781 — intervention group
Group type: EXPERIMENTAL
Intervention: PBMT + cryotherapy
Number of subjects: 50
Study 27624781 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy
Number of subjects: 50
Study 27624781 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy + PBMT
Number of subjects: 50
Study 27624781 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 24592952 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral zinc gluconate (26 mg zinc twice daily for 14 days)
Number of subjects: 0
Study 23303986 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazoxide 100 mg orally three times daily for 10 days
Number of subjects: 17
Study 23303986 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched controls without PCOS)
Number of subjects: 17
Study 23303986 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazoxide treatment
Number of subjects: 17
Study 20716348 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma and standard-of-care fixation
Number of subjects: 0
Study 20716348 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care fixation alone
Number of subjects: 0
Study 20716348 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-angle screw and plate fixation system
Number of subjects: 0
Study 18038603 — intervention group
Group type: COMPARATOR
Intervention: Standard antituberculosis therapy (Group 1)
Number of subjects: 154
Study 18038603 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard antituberculosis therapy + paravasal lymphotrophic immunological correction (Group 2)
Number of subjects: 154
Study 18038603 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual regimens of antituberculous drugs (Group 3)
Number of subjects: 154
Study 18038603 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual regimens during immunological correction (Group 4)
Number of subjects: 154
Study 15788294 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-reading arm (radiographs interpreted by an oncologist only)
Number of subjects: 869
Study 15788294 — intervention group
Group type: COMPARATOR
Intervention: Double-reading arm (oncologist and then a radiologist independently interpreted plain radiographs)
Number of subjects: 869
Study 15788294 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-reading arm
Number of subjects: 869
Study 15510746 — intervention group
Group type: EXPERIMENTAL
Intervention: FK‐506 eyedrops (0.5 mg/ml) and TobraDex eyedrops
Number of subjects: 56
Study 15510746 — intervention group
Group type: COMPARATOR
Intervention: 1% CsA eyedrops and TobraDex eyedrops
Number of subjects: 56
Study 9805320 — intervention group
Group type: EXPERIMENTAL
Intervention: Working memory task
Number of subjects: 0
Study 9805320 — intervention group
Group type: COMPARATOR
Intervention: Vigilance task
Number of subjects: 0
Study 9805320 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance and degree of activation
Number of subjects: 0
Study 7625343 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group fed formulas with protein-energy ratios of 3.73 g/MJ (1.56 g/100 kcal) from 8 to 27 days, decreasing to 2.99 g/MJ (1.25 g/100 kcal) from 84 to 111 days.
Number of subjects: 0
Study 7625343 — intervention group
Group type: COMPARATOR
Intervention: Control group (details not specified in the abstract).
Number of subjects: 0
Study 7625343 — intervention group
Group type: COMPARATOR
Intervention: Reference group (details not specified in the abstract).
Number of subjects: 0
Study 2476759 — intervention group
Group type: EXPERIMENTAL
Intervention: Medtronic 6957J lead with an electrically active myocardial screw‐helix
Number of subjects: 0
Study 2476759 — intervention group
Group type: COMPARATOR
Intervention: Cordis 329‐101P lead with an inactive helix and a porous tip electrode
Number of subjects: 0
Study 2476759 — intervention group
Group type: EXPERIMENTAL
Intervention: Medtronic 6957J lead
Number of subjects: 0
Study 2476759 — intervention group
Group type: COMPARATOR
Intervention: Cordis 329‐101P lead
Number of subjects: 0
Study 357213 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 10‐9359 at 25 mg t.i.d.
Number of subjects: 27
Study 357213 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 10‐9359 at 50 mg b.i.d.
Number of subjects: 27
Study 29745885 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab plus methotrexate
Number of subjects: 60
Study 29745885 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 60
Study 29745885 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 60
Study 29745885 — intervention group
Group type: COMPARATOR
Intervention: Control group (not achieving sDFR)
Number of subjects: 60
Study 28063805 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal Counseling Group (PCG)
Number of subjects: 171
Study 28063805 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall rates of breastfeeding in PCG
Number of subjects: 171
Study 28063805 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 171
Study 28063805 — intervention group
Group type: COMPARATOR
Intervention: Overall rates of breastfeeding in CG
Number of subjects: 171
Study 25762753 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cues
Number of subjects: 76
Study 25762753 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress cues
Number of subjects: 76
Study 25762753 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-stress cue craving
Number of subjects: 76
Study 25762753 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-stress cue stress
Number of subjects: 76
Study 25762753 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-stress cue negative affect
Number of subjects: 76
Study 25762753 — intervention group
Group type: EXPERIMENTAL
Intervention: Response to smoking cues
Number of subjects: 76
Study 23684358 — intervention group
Group type: EXPERIMENTAL
Intervention: MIROX strategy (6 FOLFOX7 cycles followed by 6 FOLFIRI cycles)
Number of subjects: 39
Study 23684358 — intervention group
Group type: COMPARATOR
Intervention: sLV5FU2 (12 cycles of simplified LV5FU2)
Number of subjects: 39
Study 23684358 — intervention group
Group type: EXPERIMENTAL
Intervention: MIROX strategy
Number of subjects: 39
Study 20495110 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-density gas mixture (60% helium and 40% O₂)
Number of subjects: 30
Study 20495110 — intervention group
Group type: EXPERIMENTAL
Intervention: O₂ supplementation (40%)
Number of subjects: 30
Study 20495110 — intervention group
Group type: COMPARATOR
Intervention: Room air
Number of subjects: 30
Study 18381513 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia (33 degrees C to 34 degrees C) for 72 hours with continuous morphine infusion
Number of subjects: 16
Study 18381513 — intervention group
Group type: COMPARATOR
Intervention: Normothermia with continuous morphine infusion
Number of subjects: 16
Study 18381513 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia
Number of subjects: 16
Study 18381513 — intervention group
Group type: COMPARATOR
Intervention: Normothermia
Number of subjects: 16
Study 18381513 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia with morphine infusion rate >10 microg/kg per h
Number of subjects: 16
Study 17079365 — intervention group
Group type: EXPERIMENTAL
Intervention: Core decompression group
Number of subjects: 33
Study 17079365 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative group
Number of subjects: 33
Study 17079365 — intervention group
Group type: COMPARATOR
Intervention: Combined necrotic angle of </=190 degrees (low-risk group)
Number of subjects: 33
Study 17079365 — intervention group
Group type: COMPARATOR
Intervention: Combined necrotic angle of >/=240 degrees (high-risk group)
Number of subjects: 33
Study 17079365 — intervention group
Group type: COMPARATOR
Intervention: Combined necrotic angle between 190 degrees and 240 degrees (moderate-risk group)
Number of subjects: 33
Study 12690024 — intervention group
Group type: EXPERIMENTAL
Intervention: Responsible sexuality education programme (RSP)
Number of subjects: 399
Study 12690024 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 399
Study 11910617 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein dietary supplements containing 118 mg of isoflavones (daidzein, genistein, glycitein and their respective glycosides)
Number of subjects: 94
Study 11910617 — intervention group
Group type: COMPARATOR
Intervention: Placebo (casein)
Number of subjects: 94
Study 8834027 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol therapy
Number of subjects: 98
Study 8834027 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 8834027 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent bleeding episode
Number of subjects: 98
Study 8834027 — intervention group
Group type: COMPARATOR
Intervention: Non-bleeders
Number of subjects: 98
Study 1282364 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha therapy (3 million units daily for the first month, then thrice weekly for 5 months)
Number of subjects: 10
Study 1282364 — intervention group
Group type: COMPARATOR
Intervention: Control group (no therapy)
Number of subjects: 10
Study 1282364 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha therapy
Number of subjects: 10
Study 1282364 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha therapy and Control group
Number of subjects: 10
Study 6374403 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple intrathecal (IT) chemotherapy (methotrexate, hydrocortisone, cytosine arabinoside) starting on day 1 of treatment (Arm 3)
Number of subjects: 0
Study 6374403 — intervention group
Group type: COMPARATOR
Intervention: Other regimens (Arms 1, 2, and 4) where CNS prophylaxis was initiated after complete marrow remission
Number of subjects: 0
Study 6374403 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple IT chemoprophylaxis during induction therapy (Arm 3)
Number of subjects: 0
Study 6374403 — intervention group
Group type: COMPARATOR
Intervention: Other regimens (Arms 1, 2, and 4)
Number of subjects: 0
Study 30316185 — intervention group
Group type: EXPERIMENTAL
Intervention: Video game training (15 hours over five weeks)
Number of subjects: 35
Study 29669139 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 100 mg + furosemide 20 mg
Number of subjects: 54
Study 29669139 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional counseling to sodium-restricted diet plus placebo pill
Number of subjects: 54
Study 29669139 — intervention group
Group type: COMPARATOR
Intervention: Placebo pill
Number of subjects: 54
Study 26482684 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Number of subjects: 105
Study 26482684 — intervention group
Group type: COMPARATOR
Intervention: Modified Ranawat suspension
Number of subjects: 105
Study 24313446 — intervention group
Group type: EXPERIMENTAL
Intervention: Action and coping planning strategies (n = 59)
Number of subjects: 115
Study 24313446 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 56)
Number of subjects: 115
Study 23044294 — intervention group
Group type: COMPARATOR
Intervention: Permanent polymer sirolimus-eluting stent (PP-SES)
Number of subjects: 105
Study 23044294 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymer free paclitaxel-eluting stent (PF-PES)
Number of subjects: 105
Study 19540483 — intervention group
Group type: EXPERIMENTAL
Intervention: Testicular sperm extraction (TESE)
Number of subjects: 57
Study 17432691 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiaoshen Tonglin Decoction (TTD) for 60 days
Number of subjects: 108
Study 17432691 — intervention group
Group type: COMPARATOR
Intervention: Terazosin tablet for 60 days
Number of subjects: 108
Study 16535996 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfacalcidol 5 micrograms/day for 5 days
Number of subjects: 15
Study 16535996 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects and NIND patients)
Number of subjects: 15
Study 12010650 — intervention group
Group type: EXPERIMENTAL
Intervention: Iscador Quercus special (IQ)
Number of subjects: 47
Study 12010650 — intervention group
Group type: EXPERIMENTAL
Intervention: Iscador Pini (IP)
Number of subjects: 47
Study 12010650 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 10363731 — intervention group
Group type: EXPERIMENTAL
Intervention: bupropion SR 150 to 400 mg/d
Number of subjects: 360
Study 10363731 — intervention group
Group type: EXPERIMENTAL
Intervention: sertraline 50 to 200 mg/d
Number of subjects: 360
Study 10363731 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 360
Study 7734255 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% mepivacaine with adrenaline 40 ml, arm adducted
Number of subjects: 90
Study 7734255 — intervention group
Group type: COMPARATOR
Intervention: 1% mepivacaine with adrenaline 40 ml, arm abducted
Number of subjects: 90
Study 7734255 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% mepivacaine 20 ml mixed with contrast agent 20 ml, arm adducted
Number of subjects: 90